Stem cell treatment of Cartilage injuries India
Cartilage injuries of the knee are prevalent in the young population. They result from sports injuries, knee deformities, accidents etc. Here Stem cell treatment of knee cartilage lesions are...
By: ALAMPALLAM VENKATACHALAM
See original here:
Stem cell treatment of Cartilage injuries India - Video
Albany, NY (PRWEB) September 15, 2014
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..
View Full Report at http://www.marketresearchreports.biz/analysis/223134
Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134
The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.
Browse All Published Reports by Same Publisher at http://www.marketresearchreports.biz/publisher/67
Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOSTs adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).
In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.
Related Reports
Dallas, TX (PRWEB) September 15, 2014
Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc.
Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.
Order a copy of this report at http://www.chinamarketresearchreports.com/contacts/purchase.php?name=114908 .
The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.
Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOSTs adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).
Complete report is available at http://www.chinamarketresearchreports.com/114908.html .
In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.
Global and China Stem Cell Industry Report, 2014-2017 highlights the followings:
Classification, application, industry chain definition, etc. of stem cells; Major enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry; Policies, upstream/midstream/downstream development, etc. of China stem cell industry; Operation, stem cell business, etc. of 6 upstream companies and 18 midstream/downstream companies worldwide.
Read the original here:
Global and China Stem Cell Industry Report 2014-2017 Now Available at ChinaMarketResearchReports.com
Watch Ulrika's appeal. Can you help, before it is too late?
Time is running out for brave Ulrika Dandekar who is desperately in need of a stem cell transplant after being diagnosed with a rare type of blood cancer.
For Ulrika, aged 21, from Solihull, has been readmitted to hospital after discovering more than 15 cancerous lumps on her body.
She has undergone another round of chemotherapy in the hope of combating the cancer, called Anaplastic Lymphoma, at Heartlands Hospital, and will have to wait at least two weeks before she will find out if its worked.
VIEW GALLERY
Previous treatment had seen a reduction in the size of another cancerous growth
But during a holiday to Turkey in August, Ulrika, known as Riya, noticed that a small lump on the side of her body, which was thought to be an insect bite, had grown.
She explained: I had been given the okay to go on holiday to Turkey with my mum, but just before going away, I noticed a small lump which looked just like an insect bite.
The doctors thought it was nothing to worry about but I was given antibiotics. However, when we got abroad it just kept changing and growing every day.
My mum kept taking pictures of it and emailing them back to our doctor to keep him up-to-date with what was happening, although coming back early would not have made a difference.
See the original post:
Watch brave cancer battler Ulrika Dandekar make a desperate appeal for a stem cell donor
Stem Cell Therapy for Osteoarthritis
Ross Hauser, MD explains Stem Cell Prolotherapy using whole bone marrow. If you have osteoarthritis and are interested in how stem cell therapy may help you, we would love to see you in one...
By: Caring Medical and Rehabilitation Services
The rest is here:
Stem Cell Therapy for Osteoarthritis - Video
Spinal cord injury - Case Study- Stem cell therapy- Giostar
a brief introduction to Giostar and its Stem cell therapy Dr.Divyang Patel (MD) a spine surgeon at Giostar- INDIA, briefs about a case of cervical spine injury, which is also examined by a...
By: Devang Parmar
Originally posted here:
Spinal cord injury - Case Study- Stem cell therapy- Giostar - Video
Comments(0)
Scientists are celebrating a breakthrough in stem cell research.
A type of human stem cell has been replicated in a lab for the first time in history.
The cells, previously impossible to duplicate, have been recreated to the equivalent of those between seven and nine days old the same as found in an embryo before it implants in the womb.
The creation of the human pluripotent cells opens a door for specialised cells to be created in the future for use in regenerative medicine.
The Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute led the research, which was carried out by both British and Japanese academics.
Professor Austin Smith, director, said: "Our findings suggest that it is possible to rewind the clock to achieve true ground state pluripotency in human cells.
"These cells may represent the real starting point for formation of tissues in the human embryo. We hope that in time they will allow us to unlock the fundamental biology of early development, which is impossible to study directly in people."
The "reset" cells could be used as "raw material" for therapies, as well as diagnostic tools and drug screenings.
Scientists also hope that after further studying, the cells will help them learn more about how an embryo develops correctly, and how miscarriages and developmental disorders are caused.
See more here:
Significant milestone in stem cell research at The Wellcome Trust - Medical Research Council institute
Cambridge scientists have successfully reset human pluripotent stem cells to the earliest developmental state equivalent to cells found in an 7-9 day old embryo before it implants in the womb.
The researchers believe that these pristine stem cells, which have until now been impossible to replicate in the lab, could mark the true starting point for human development.
It is hoped that the discovery, published in Cell, will lead to a better understanding of human development and could in future allow the production of safe and more reproducible starting materials for a wide range of applications including cell therapies.
Researchers led by the Wellcome Trust-Medical Research Council (MRC) Cambridge Stem Cell Institute at the University of Cambridge, have managed to induce a ground state by rewiring the genetic circuitry in human embryonic and induced pluripotent stem cells. Their reset cells share many of the characteristics of authentic nave embryonic stem cells isolated from mice, suggesting that they represent the earliest stage of development.
Human pluripotent stem cells, which have the potential to become any of the cells and tissues in the body, can be made in the lab either from cells extracted from a very early stage embryo or from adult cells that have been induced into a pluripotent state.
To date, scientists have struggled to generate human pluripotent stem cells that are truly pristine researchers have only been able to derive cells which have advanced slightly further down the developmental pathway. These bear some of the early hallmarks of differentiation into distinct cell types theyre not a truly blank slate. This may explain why existing human pluripotent stem cell lines often exhibit a bias towards producing certain tissue types in the laboratory.
Capturing embryonic stem cells is like stopping the developmental clock at the precise moment before they begin to turn into distinct cells and tissues, explains Professor Austin Smith, Director of the Stem Cell Institute, who co-authored the paper.
Scientists have perfected a reliable way of doing this with mouse cells, but human cells have proved more difficult to arrest and show subtle differences between the individual cells. Its as if the developmental clock has not stopped at the same time and some cells are a few minutes ahead of others.
The process of generating stem cells in the lab is easier to control in mouse cells, which can be frozen in a state of nave pluripotency using a protein called LIF. Human cells are not as responsive to LIF, so they must be controlled in a different way that involves switching key genes on and off. For this reason scientists have been unable to generate human pluripotent cells that are as primitive or as consistent as mouse embryonic stem cells.
The researchers overcame this problem by introducing two genes NANOG and KLF2 causing the network of genes that control the cell to reboot and induce the nave pluripotent state. Importantly, the introduced genes only need to be present for a short time. Then, like other stem cells, reset cells can self-renew indefinitely to produce large numbers, are stable and can differentiate into other cell types, including nerve and heart cells.
Go here to read the rest:
Stem cell advance made by Cambridge scientists
Tokyo, Sep 13 (IANS): Japanese researchers have successfully implanted lab-grown retinal tissue from induced pluripotent stem cells (iPS) into a woman in her 70s - the world's first recipient of stem cells.
In a two-hour procedure, a team of three eye specialists led by Yasuo Kurimoto of the Kobe City Medical Center General Hospital transplanted a 1.3 by 3.0 millimetre sheet of retinal pigment epithelium cells into an eye of the woman who was suffering from an age-related macular degeneration.
The procedure was performed at the Institute of Biomedical Research and Innovation Hospital, next to the RIKEN Center for Developmental Biology (CDB) where ophthalmologist Masayo Takahashi had developed and tested the cells.
Kurimoto performed the procedure in a mere four days after a health ministry committee gave Takahashi clearance for the human trials, the scientific journal Nature reported.
She took the patient's skin cells, converted them into iPS cells and then coaxed them to differentiate into retinal cells.
The patient experienced no effusive bleeding or other serious problems.
"The patient took on all the risks that came along with treatment and surgery. I have deep respect for the bravery she showed in resolving to go through with it," Kurimoto said in a statement.
Kurimoto also thanked Shinya Yamanaka, a stem-cell scientist at the Kyoto University "without whose discovery of iPS cells, this clinical research would not be possible".
Yamanaka shared the 2012 Nobel Prize in Physiology or Medicine for his work.
"We have taken a momentous first step toward regenerative medicine using iPS cells," Takahashi concluded.
Read more:
World's first lab grown stem cells implanted
TOKYO: Japanese researchers on Friday (Sep 12) conducted the world's first surgery to implant "iPS" stem cells in a human body in a major boost to regenerative medicine, two institutions involved said.
A female patient in her 70s with age-related macular degeneration (AMD), a common medical condition that can lead to blindness in older people, had a sheet of retina cells that had been created from iPS cells implanted. "It is the first time in the world that iPS cells have been transplanted into a human body," a spokeswoman for Riken, one of the research institutions, told AFP.
The research team used induced Pluripotent Stem (iPS) cells - which have the potential to develop into any cell in the body - that had originally come from the skin of the patient. Until the discovery of iPS several years ago, the only way to obtain stem cells was to harvest them from human embryos.
"We feel very much relieved," ophthalmologist Masayo Takahashi, the leader of the project at Riken, told a news conference after the surgery in Kobe. "We want to take it as a big step forward. But we must go on and on from here."
In a statement, the institution said that "no serious adverse phenomena such as excessive bleeding occurred" during the two-hour procedure. The surgery is still at an experimental stage, but if it is successful, doctors hope it will stop the deterioration in vision that comes with AMD.
The patient - one of six expected to take part in the trial - will be monitored over the next four years to determine how well the implants have performed, whether the body has accepted them and if they have become cancerous.
AMD, a condition that is incurable at present, affects mostly middle-aged and older people and can lead to blindness. It afflicts around 700,000 people in Japan alone.
The study was being carried out by researchers from government-backed research institution Riken and the Institute of Biomedical Research and Innovation Hospital.
Stem cell research is a pioneering field that has excited many in the scientific community with the potential they believe it offers. Stem cells are infant cells that can develop into any part of the body. Harvesting from human embryos is controversial because it requires the destruction of the embryo, a process to which religious conservatives, among others, object.
Groundbreaking work done in 2006 by Shinya Yamanaka at Kyoto University, a Nobel Laureate in medicine last year, succeeded in generating stem cells from adult skin tissue.
Here is the original post:
Japan carries out first iPS stem cell retina surgery